[ad_1]
Evan Y. Yu, MD, professor in the Department of Medical Oncology of the Faculty of Medicine at the University of Washington, a member of the Clinical Research Division of the Fred Hutchinson Cancer Research Center and director of the Clinical Trials Center of the Department of Genitourinary Medical Oncology of the Seattle Cancer Care Alliance. KEYNOTE-365 Phase Ib / II Key Findings: Evaluating Different Innovative Combinations in Patients With Castration-Resistant Metastatic Prostate Cancer (mCRPC)
Forty-one patients were treated in cohort A with pembrolizumab (Keytruda) plus olaparib (Lynparza); this combination induced modest response rates in unselected molecular patients with mCRPC. This represents a heavily pretreated patient population, where approximately 25% of patients had previously received all treatment strategies, including abiraterone acetate (Zytiga), enzalutamide (Xtandi), docetaxel and cabazitaxel (Jevtana), according to Yang.
The overall response rate (ORR) was 7% with a median follow-up of 11.4 months. Although this ORR is low, it is significant for this patient population, says Yang. In patients with soft tissue disease, 14% had a significant decrease in PSA, compared to 12% in the total population.
According to Yang, it is difficult to confirm non-targeted lesions in bone metastases or bone scans in prostate cancer, which may appear more serious. In all but one patient who had responses, they had progressed in non-target lesions and bone lesions. According to Yang, it is common to see responses with immunotherapy, but it is rare to see a short-term response followed by progression elsewhere.
One possibility for this is that microenvironments of bones and soft tissues are different in mCRPC, so perhaps this treatment would work better for soft tissue. Yang concludes that these hypotheses must be validated.
For more resources and information on cancer treatments targeting prostate cancer: http: //targetedonc.com/resouce-center …
Source link
